Complete responses (CR) in patients receiving atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).

被引：0
|
作者：
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy Vladimirovich
Merle, Philippe
Kaseb, Ahmed Omar
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Ding, Beiying
Zhu, Andrew X.
Cheng, Ann-Lii
机构：
[1] UCLA, Jonsson Comprehens Canc Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA
[2] Jinling Hosp, Peoples Liberat Army Canc Ctr, Nanjing, Peoples R China
[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[4] Univ Med Ctr, Mainz, Germany
[5] Gustave Roussy Canc Campus Grand Paris, Villejuif, France
[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
[7] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[8] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea
[9] NN Blokhin Minist Hlth, Russian Oncol Res Ctr, Moscow, Russia
[10] Hosp La Croix Rousse, Lyon, France
[11] Univ Texas MD Anderson Canc Ctr, GI Med Oncol Dept, Houston, TX 77030 USA
[12] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA
[13] Beckman Res Inst, Duarte, CA USA
[14] Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol, Tainan, Taiwan
[15] Genentech Inc, San Francisco, CA 94080 USA
[16] Roche Prod Dev, Shanghai, Peoples R China
[17] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[18] Natl Taiwan Univ Hosp, Taipei, Taiwan
[19] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4596
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Randomised efficacy and safety results for atezolizumab (Atezo) plus bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
    Hsu, C-H.
    Lee, M. S.
    Lee, K-H.
    Numata, K.
    Stein, S.
    Verret, W.
    Hack, S.
    Spahn, J.
    Liu, B.
    Huang, C.
    He, R.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Randomised efficacy and safety results for atezolizumab (Atezo) plus bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
    Lee, M.
    Ryoo, B-Y.
    Hsu, C-H.
    Numata, K.
    Stein, S.
    Verret, W.
    Hack, S.
    Spahn, J.
    Liu, B.
    Abdullah, H.
    He, R.
    Lee, K-H.
    ANNALS OF ONCOLOGY, 2019, 30 : 875 - 875
  • [43] Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Shao, Yu-Yun
    Finn, Richard S.
    Galle, Peter R.
    Ducreux, Michel
    Cheng, Ann-Lii
    Yamashita, Tatsuya
    Koga, Hironori
    Take, Ryosuke
    Yamada, Kyoko
    Asakawa, Takashi
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (04) : 401 - 412
  • [44] Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
    Yim, Sun Young
    Lee, Sung Hwan
    Baek, Seung-Woo
    Sohn, Bohwa
    Jeong, Yun Seong
    Kang, Sang-Hee
    Park, Kena
    Park, Hyewon
    Lee, Sunyoung S.
    Kaseb, Ahmed O.
    Park, Young Nyun
    Leem, Sun-Hee
    Curran, Michael A.
    Kim, Ji Hoon
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [45] Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
    Margherita Rimini
    Mara Persano
    Toshifumi Tada
    Goki Suda
    Shigeo Shimose
    Masatoshi Kudo
    Jaekyung Cheon
    Fabian Finkelmeier
    Ho Yeong Lim
    José Presa
    Gianluca Masi
    Changhoon Yoo
    Sara Lonardi
    Fabio Piscaglia
    Takashi Kumada
    Naoya Sakamoto
    Hideki Iwamoto
    Tomoko Aoki
    Hong Jae Chon
    Vera Himmelsbach
    Tiziana Pressiani
    Margarida Montes
    Caterina Vivaldi
    Caterina Soldà
    Atsushi Hiraoka
    Takuya Sho
    Takashi Niizeki
    Naoshi Nishida
    Christoph Steup
    Masashi Hirooka
    Kazuya Kariyama
    Joji Tani
    Masanori Atsukawa
    Koichi Takaguchi
    Ei Itobayashi
    Shinya Fukunishi
    Kunihiko Tsuji
    Toru Ishikawa
    Kazuto Tajiri
    Hironori Ochi
    Satoshi Yasuda
    Hidenori Toyoda
    Chikara Ogawa
    Takashi Nishimura
    Takeshi Hatanaka
    Satoru Kakizaki
    Noritomo Shimada
    Kazuhito Kawata
    Fujimasa Tada
    Hideko Ohama
    Targeted Oncology, 2023, 18 : 221 - 233
  • [46] IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study
    Han Chong Toh
    Galle, Peter R.
    Zhu, Andrew X.
    Nicholas, Alan
    Gaillard, Vincent
    Ducreux, Michel
    Cheng, Ann-Lii
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Hatanaka, Takeshi
    Hiraoka, Atsushi
    Tada, Toshifumi
    Kakizaki, Satoru
    LIVER CANCER, 2024, 13 (06) : 669 - 670
  • [48] Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
    Rimini, Margherita
    Persano, Mara
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Masi, Gianluca
    Yoo, Changhoon
    Lonardi, Sara
    Piscaglia, Fabio
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Pressiani, Tiziana
    Montes, Margarida
    Vivaldi, Caterina
    Solda, Caterina
    Hiraoka, Atsushi
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    TARGETED ONCOLOGY, 2023, 18 (02) : 221 - 233
  • [49] Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Yamashita, Tatsuya
    Koga, Hironori
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (06) : 671 - 673
  • [50] Reply to correspondence on "Genomic biomarkersto predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"
    Kanzaki, Hiroaki
    Hoshida, Yujin
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
12345